Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

BACKGROUND: The tumor antigen NY-ESO-1 has been shown to be an effective target for transgenic adoptive cell therapy (ACT) for the treatment of sarcoma and melanoma. However, despite frequent early clinical responses, many patients ultimately develop progressive disease. Understanding the mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Frankiw, Luke, Singh, Arun, Peters, Cole, Comin-Anduix, Begoña, Berent-Maoz, Beata, Macabali, Mignonette, Shammaie, Kiana, Quiros, Crystal, Kaplan-Lefko, Paula, Baselga Carretero, Ignacio, Ribas, Antoni, Nowicki, Theodore Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173990/
https://www.ncbi.nlm.nih.gov/pubmed/37156551
http://dx.doi.org/10.1136/jitc-2023-006930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173990/
https://www.ncbi.nlm.nih.gov/pubmed/37156551
http://dx.doi.org/10.1136/jitc-2023-006930

Ejemplares similares